临床研究管道对于确保持续开发新疗法至关重要，从而为癌症患者提供安全有效的选择。不幸的是，自 COVID-19 大流行以来，由于关键流程中未发现的系统性低效率，进展已经放缓。为了启动有关如何重振临床研究的讨论，癌症免疫治疗协会 (SITC) 主办了一次虚拟峰会，对问题进行了特征分析并形成了潜在的解决方案。本评论旨在强调临床研究面临的危机，并激发有关如何在未来更好地为患者服务的全领域讨论。© 作者（或其雇主）2024。CC BY 允许重复使用-NC。不得商业再利用。请参阅权利和权限。由英国医学杂志出版。

The clinical research pipeline is critical to ensuring continued development of novel treatments that can offer patients with cancer safe and effective options. Unfortunately, progress has slowed since the COVID-19 pandemic due to uncovered, systemic inefficiencies across critical processes. Towards initiating discussion on how to reinvigorate clinical research, the Society for Immunotherapy of Cancer (SITC) hosted a virtual summit that characterized issues and formed potential solutions. This commentary serves to highlight the crisis facing clinical research as well as stimulate field-wide discussion on how to better serve patients into the future.© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.